Results 211 to 220 of about 7,174,113 (351)

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Hepatitis B knowledge among nursing students at Jiblah University for medical and health sciences. [PDF]

BMC Public Health
Kaid Al-Mohani S, Alahdal A, Almohtdi A, Alkhtib M, Almzgagi W, Marzh M, Almzgagi H.   +6 more
europepmc   +1 more source

Transfer of Fitzsimons Army Medical Center to the University of Colorado Health Sciences Center

, 1996
University of Colorado Health Sciences Center
openalex   +1 more source

Empirical Study of Knowledge, Attitude and Practice towards to Radiation Health Hazards of Cell Phone: a Case Study on Medical Science Students [PDF]

, 2020
Mansooreh Dehghani, Samaneh Shahsavani, Fatemeh Jamshidi, Narges Shamsedini   +3 more
openalex  

Science and Human Health [PDF]

Science, 1974
openaire   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Appendix. Official Organ of the Health Sciences Library. June 2014, The

, 2014
Multiple authors, Health Sciences Library   +1 more
openalex   +1 more source

The Science of Health [PDF]

BMJ, 1942
openaire   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source